14 patents
Utility
Compounds for the modulation of Myc activity
12 Sep 23
Jason J. Marineau, Peter B. Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 25 Aug 21
Utility
Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
20 Sep 22
The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists.
Mei Wei Chen, Cindy Collins, Matthew Lucas Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael Robert McKeown, David A. Orlando
Filed: 8 May 20
Utility
Inhibitors of cyclin dependent kinase 7 (CDK7)
26 Apr 22
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing.
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro, Henri Piras, Kenneth Matthew Whitmore, Kate-Lyn Lund
Filed: 16 Jan 19
Utility
Compounds for the modulation of MYC activity
15 Mar 22
Jason J. Marineau, Kevin Sprott, Stephane Ciblat, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier, Boubacar Sow, Peter B. Rahi, Robin Larouche-Gauthier, Lauren Berstler
Filed: 8 Sep 17
Utility
Compounds for the modulation of Myc activity
21 Sep 21
Jason J. Marineau, Peter B. Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 3 Jun 16
Utility
Compositions of cyclin dependent kinase 7 (CDK7) inhibitor
10 Aug 21
The present invention provides, in part, compositions comprising an inhibitor of cyclin-dependent kinase 7 (CDK7) and sulfobutyl ether-β-cyclodextrin.
Neera Jain
Filed: 3 Apr 18
Utility
Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
6 Jul 21
Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists.
Michael Robert McKeown, Christopher Fiore, Matthew Lucas Eaton, Emily Payton Lee, Christian Fritz
Filed: 14 Jan 19
Utility
Heteroaromatic compounds useful for the treatment of proliferative diseases
22 Jun 21
Stephane Ciblat, Patrick Deroy, Nathanael Gray, Melissa Leblanc, Jason J. Marineau, Joel Moore, Kevin Sprott, Tinghu Zhang, M. Arshad Siddiqui, Anzhelika Kabro, Serge Leger, Stephanie Roy, Darby Schmidt, Dana K. Winter, Michael Bradley, Tom Miller
Filed: 5 Dec 18
Utility
Pyrrolotriazine compounds and methods of inhibiting TAM kinases
22 Jun 21
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.
David Moebius, Jason J. Marineau, Yi Zhang, Claudio Edmundo Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Stephane Ciblat, Clint James, Amandine Xolin, Sylvain Bernard, Malay Doshi
Filed: 9 Oct 18
Utility
Inhibitors of cyclin-dependent kinase 7 (CDK7)
14 Dec 20
Stephane Ciblat, Anzhelika Kabro, Melissa Leblanc, Serge Leger, Jason J. Marineau, Tom Miller, Stephanie Roy, Darby Schmidt, M. Arshad Siddiqui, Kevin Sprott, Dana K. Winter, Amy Ripka, Dansu Li, Guoli Zhang
Filed: 14 May 19
Utility
Compounds for the modulation of myc activity
28 Sep 20
Jason J. Marineau, Peter B. Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 4 Jun 16
Utility
Inhibitors of cyclin-dependent kinase 7 (CDK7)
10 Aug 20
The present invention provides various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, solvates (e.g., hydrates), stereoisomer, tautomers, isotopic and other specified forms thereof.
Jason J. Marineau, Michael Bradley, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro
Filed: 10 Feb 20
Utility
Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
29 Jun 20
The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists.
Mei W. Chen, Cindy Collins, Matthew L. Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael R. McKeown, David A. Orlando
Filed: 19 Feb 18
Utility
Inhibitors of cyclin-dependent kinase 7 (CDK7)
30 Dec 19
The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof.
Kevin Sprott, Jason J. Marineau, Darby Schmidt, Michael Bradley, Stephane Ciblat, M. Arshad Siddiqui, Anzhelika Kabro, Melissa Leblanc, Serge Leger, Stephanie Roy, Dana K. Winter, Tom Miller, Amy Ripka, Dansu Li
Filed: 9 Jul 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first